Nyxoah S.A. (NYXH) is a publicly traded company in the Healthcare — Medical - Specialties industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Analysis Summary
Nyxoah S.A. reported revenue of $10.0M in the most recent fiscal year, growing at a 5-year CAGR of 170.6%.
Trailing-twelve-month margins: gross margin 51.3%, operating margin -383.1%, net margin -434.7%.
At the current price of $1.55, NYXH has negative trailing earnings (P/E not meaningful) and an ROE of -179.71%. Market capitalisation stands at $155M.
Balance sheet quality for NYXH: current ratio of 1.3, net cash position of $5.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.55 |
| Market Cap | $155M |
| Exchange | NASDAQ |
| Country | BE |
Valuation Ratios
| Price / Book | 0.91 |
| EV / EBITDA | -1.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -179.71% |
| Return on Invested Capital | -59.89% |
| Return on Assets | -58.46% |
| Gross Margin | 51.31% |
| Operating Margin | -383.05% |
| Net Margin | -434.72% |
Financial Health
| Debt / Equity | 0.63 |
| Current Ratio | 2.38 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NYXH | Nyxoah S.A. | $155M | 0.91 | -179.7% | |
| ALC | Alcon Inc. | $32.2B | 51.85 | 1.52 | |
| 0A0D.L | Alcon Inc. | $27.1B | |||
| STE | STERIS plc | $20.5B | |||
| 0JZ2.L | Masimo Corporation | $9.5B | 9.69 | -21.0% | |
| 0QLQ.L | Ypsomed Holding AG | $4.8B | |||
| 0A05.L | Medacta Group S.A. | $2.3B |
Price Performance
| 1 month | -3.13% |
| 3 months | -3.13% |
| Year-to-date | -66.30% |
| 1 year | -66.74% |
| 3 years | -80.62% |
52-Week Range
| 52-week High | $6.87 |
| 52-week Low | $1.26 |
| Avg Volume (90d) | 354K |
Related companies: CATX · GNFT · IVVD · KRMD · OABI · OSUR · PRE
Explore sector: Healthcare · Medical - Specialties
More sections of NYXH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks